20-F: BioNTech SE Releases Annual Report on Form 20-F for Fiscal Year 2024

BioNTech SE files its annual report on Form 20-F, detailing the company's business, operations, and financial performance for the year ended December 31, 2024.

Summary

• BioNTech SE has released its annual report on Form 20-F for the fiscal year ended December 31, 2024.
• The report includes detailed information about the company's business, operations, and financial performance.
• The company's ordinary shares outstanding as of March 3, 2025, were 239,970,804.
• The report highlights the company's focus on developing immunotherapies for cancer, infectious diseases, and other serious conditions.
• The company's key objectives include developing an innovative oncology pipeline and building a sustainable respiratory infectious disease vaccine business.
• The report mentions the company's COVID-19 vaccine, Comirnaty, and its efforts to adapt the vaccine to new variants.
• The company is developing other product candidates and services in an environment of rapid technological and scientific change.
• The company faces significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for its COVID-19 vaccine.
• The company's COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.
• The company's operating results may fluctuate significantly, which makes its future operating results difficult to predict.
• The company is subject to various risks, including those related to the demand for its COVID-19 vaccine, competition, and regulatory approvals.
• The company is developing other product candidates and services in an environment of rapid technological and scientific change, and its failure to effectively compete would prevent it from achieving significant market penetration.

Sentiment

Score: 6

Explanation: The document is a factual report, but contains both positive and negative elements. The company is performing well in some areas, but faces challenges in others. The sentiment is neutral overall.

Positives

• The report highlights the company's focus on developing immunotherapies for cancer, infectious diseases, and other serious conditions.
• The report mentions the company's COVID-19 vaccine, Comirnaty, and its efforts to adapt the vaccine to new variants.

Negatives

• The company faces significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for its COVID-19 vaccine.
• The company's COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.
• The company's operating results may fluctuate significantly, which makes its future operating results difficult to predict.

Risks

• Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future.
• Our reported commercial revenue is partially based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods.
• We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus.
• Significant adverse events may occur during our clinical trials or even after receiving regulatory approval.
• If we are unable to continue to increase our marketing and sales capabilities, we may not be able to market and sell our product candidates effectively.
• Other companies may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing and commercializing our COVID-19 vaccine or our product candidates.
• Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance necessary for commercial success.
• Our operating results may fluctuate significantly, which makes our future operating results difficult to predict.
• If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.
• As a foreign private issuer, we are exempt from a number of rules under U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies.
• Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control.
• mRNA drug development has substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.
• Our approved product and product candidates are based on novel technologies and they may be complex and difficult to manufacture.
• If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.
• We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.
• Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.

Future Outlook

The company expects that future revenues from sales of its COVID-19 vaccine will decrease as demand for vaccination wanes. The company plans to continue to invest heavily in research and development as it makes a strong drive to build out its global development organization and diversify its therapeutic area footprint. Additionally, the company plans to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing.

Industry Context

The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that BioNTech is targeting or expects to target.

Management Changes

Legal Proceedings

• Alnylam Pharmaceuticals Inc. has brought litigation against BioNTech and Pfizer regarding U.S. Patent Nos. 11,245,933; 11,382,979; 11,633,479; 11,633,480; 11,612,657; and 11,590,229.
• CureVac SE has brought litigation against BioNTech in Germany regarding three European patents, 1857122B1, 3708668B1, and 4023755B1, and three German utility models, DE202015009961, DE202015009974, and DE202021004130.
• In the United States, CureVac asserts seven U.S. patents against BioNTech and Pfizer: U.S. Patent Nos. 11,135,312; 11,149,278; 10,760,070; 11,286,492; 11,345,920; 11,596,686, and 11,667,910.
• ModernaTX, Inc. has brought litigation against BioNTech and Pfizer regarding European patents 3590949B1 and 3718565B1 in Germany, England and Wales, the Netherlands, Ireland, and Belgium, and regarding U.S. Patent Nos. 10,898,574, 10,702,600, and 10,933,127 in the United States.
• Arbutus Biopharma Corp. and Genevant Sciences GmbH have brought litigation against BioNTech and Pfizer in the United States regarding U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098.
• Promosome initiated litigation against BioNTech and Pfizer in the United States regarding U.S. Patent No. 8,853,179; it has since been dismissed with prejudice.
• Promosome LLC has initiated litigation against BioNTech and Pfizer in the Unified Patent Court (Munich Division) regarding one European patent, EP 2 401 365.
• GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC have brought litigation against BioNTech and Pfizer in the United States regarding U.S. Patent Nos. 11,638,693; 11,638,694; 11,666,534; 11,766,401; 11,786,467; 11,759,422; 11,655,475; and 11,851,660.
• We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, including alleged trade secrets of their former employers.

Related Party Transactions

• The report mentions related party transactions with ATHOS KG and Medine GmbH.
• The report mentions that the Supervisory Board granted Annemarie Hanekamp a one-time signing bonus of 1,750,000 as of her appointment. Out of this amount, 1,250,000 was paid as a cash bonus in July 2024. The remainder of 500,000 will be granted in shares (and considered owed) in July 2028 or, at the earliest possible date after a potential blackout period, provided she is still a Management Board Member on June 30, 2028.

Stakeholder Impact

• The report provides information relevant to shareholders, employees, customers, suppliers, and creditors.
• The report highlights the company's commitment to improving the health of people worldwide.
• The report discusses the company's efforts to ensure equitable access to medicine around the globe.

Next Steps

• Continue research and development of product candidates.
• Seek regulatory approvals for product candidates.
• Develop sales and marketing capabilities.
• Manage expenses.
• Protect and enforce intellectual property rights.
• Attract, hire, and retain qualified personnel.

Key Dates